Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma

Hepatology Research : the Official Journal of the Japan Society of Hepatology
Tomokazu KawaokaKazuaki Chayama

Abstract

The aim of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) between 5-fluorouracil (5-FU)-based continuous infusion chemotherapy and low-dose cisplatin (CDDP) monotherapy in patients with advanced hepatocellular carcinoma (HCC). Patients were grouped according to HAIC regimen (5-FU group, n = 317/CDDP group, n = 66). A two-to-one match was created using propensity score analysis (5-FU group, n = 102/CDDP group, n = 51). After matching, response rate (RR) and adverse events as primary end-points, and survival and progression-free survival as secondary end-points, were analyzed. In the analysis of primary end-points, the RR in the 5-FU group was significantly higher than in the CDDP group (32.4% vs. 15.7%, P = 0.033). In patients with a Child-Pugh (CP) score of 5-7, the RR in the 5-FU group was significantly higher than that in the CDDP group (36.1% vs. 15.4%, P = 0.020). In those with a CP score of 8-9, there was no significant difference in RR between the two groups (15.8% vs. 16.6%, P = 1.000). The reservoir system-related complications were 9.8% in the 5-FU group, and there was no significant difference in the incidence of grade 3/4 adverse events between the two matched groups...Continue Reading

References

Apr 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdK I Pritchard
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S Go, A A Adjei
Aug 29, 2002·Cancer Investigation·Wayne S CourtLouis S Zeiger
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Feb 22, 2008·The American Journal of Gastroenterology·Alan R Zinsmeister, Jason T Connor
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jul 30, 2009·Annals of Surgery·Pierre A ClavienMasatoshi Makuuchi
Jul 17, 2010·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Shigeki AriiMasatoshi Kudo
Aug 7, 2010·Intensive Care Medicine·Etienne GayatRaphaël Porcher
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Nov 3, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Morito MondenUNKNOWN FAIT Research Group
Dec 14, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takahiro Yamasaki, Isao Sakaida
Oct 2, 2012·Journal of Gastroenterology and Hepatology·Daisuke MiyakiKazuaki Chayama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.